Adicet Bio Inc Stock Price, News & Analysis

Adicet Bio, Inc. (NASDAQ: ACET) announced the granting of inducement awards on March 31, 2022, to two new employees as part of its 2022 Inducement Plan. The awards consist of non-qualified stock options to purchase a total of 36,000 shares at an exercise price of $19.97 per share, which reflects the closing price on the Grant Date. The options will vest progressively over four years, subject to continued employment. This plan was approved by an independent compensation committee in compliance with Nasdaq Listing Rule 5635(c)(4).

Adicet Bio, Inc. (ACET) reported positive interim findings in its Phase 1 study of ADI-001 for non-Hodgkin’s lymphoma, with complete responses observed at low dose levels. The company raised $94.2 million in net proceeds through a recent public offering, bolstering its financial position with $277.5 million in cash as of December 31, 2021. Despite a net loss of $62 million for 2021, which increased from $36.7 million in 2020, the company remains on track for key milestones in 2022, including additional clinical data expected soon.

Adicet Bio, Inc. (Nasdaq: ACET) announced the granting of inducement awards on February 28, 2022, to three new employees as part of its 2022 Inducement Plan. The awards include non-qualified stock options to purchase 87,800 shares at an exercise price of $13.08, based on the stock's closing price on the grant date. Options will vest over four years, contingent on continued employment. These awards fall outside stockholder-approved equity plans and were approved by the compensation committee in compliance with Nasdaq Listing Rule 5635(c)(4).

Adicet Bio, Inc. (NASDAQ: ACET) announced that CEO Chen Schor will participate in a virtual fireside chat at the Guggenheim 2022 Oncology Conference on February 9, 2022, at 11:30 am ET. Investors can access the live audio webcast through the company's website, with an archived replay available for 30 days post-event. Adicet Bio is focused on developing allogeneic gamma delta CAR T cell therapies targeting cancer and other diseases, emphasizing durable anti-tumor immune responses.

Adicet Bio, Inc. (Nasdaq: ACET) announced the closing of its underwritten public offering of 7,187,500 shares of common stock, which includes the full exercise of an option for an additional 937,500 shares. The offering price was set at $14.00 per share, netting approximately $100.6 million in gross proceeds before expenses. This offering was facilitated under a previously effective shelf registration with the SEC. Jefferies and Guggenheim Securities served as joint book-running managers.

Adicet Bio, Inc. (Nasdaq: ACET) has announced a public offering of 6,250,000 shares of common stock priced at $14.00 per share, aiming for gross proceeds of approximately $87.5 million. The company has granted underwriters a 30-day option to purchase an additional 937,500 shares. The offering is set to close around December 10, 2021, pending customary closing conditions. This offering is conducted under a previously effective shelf registration statement with the SEC.

Adicet Bio, Inc. (Nasdaq: ACET) has announced an underwritten public offering of its common stock, granting underwriters a 30-day option for an additional 15% of shares sold at the public offering price. The offering is contingent on market conditions. Shares will be sold under a shelf registration statement effective since March 30, 2021. Jefferies LLC and Guggenheim Securities, LLC are acting as joint book-running managers. This press release does not constitute an offer to sell or a solicitation for the purchase of securities.

Adicet Bio announced promising interim results from its Phase 1 study of ADI-001, a gamma delta CAR T cell therapy targeting B-cell Non-Hodgkin's Lymphoma. As of November 22, 2021, six patients received ADI-001, with an overall response rate (ORR) of 75% and a complete response (CR) rate of 50%. Notably, no serious adverse events were reported. The findings support the therapy's safety and potential effectiveness, highlighting its ability to offer an off-the-shelf treatment option. Further data is anticipated in the first half of 2022, showcasing the ongoing progress of Adicet's innovative platform.

Adicet Bio (Nasdaq: ACET) has announced a webcast on December 6, 2021, at 8:30 AM EST to present interim data from the Phase 1 study of ADI-001, an allogeneic gamma delta CAR T cell therapy targeting CD20 for B Cell Non-Hodgkin’s Lymphoma. This presentation will feature expert insights from Dr. Sattva Neelapu and Adicet's management team. The study aims to evaluate the safety and tolerability of ADI-001, marking a significant milestone in cancer treatment approaches.